According to ARS Pharmaceuticals, both the US Patent and Trademark Office and the European Patent Office have upheld the validity of claims in patents related to neffy epinephrine nasal spray / EURneffy adrenaline nasal spray. The company said that the USPTO upheld “key claims” in US Patent No. 10,682,414, which covers the use of aqueous epinephrine nasal spray, earlier this year and that the EPO has now upheld all claims in EP 3678649, which covers intranasal epinephrine formulations that include alkyl-glycoside.
In the US, neffy has been approved for the treatment of anaphylaxis since August 2024, and EURneffy was approved in Europe the same month. The nasal spray has recently been approved in the UK and in Japan. Currently, ARS Pharma’s patents related to neffy will provide coverage until 2039 or beyond, the company said.
ARS Pharma President and CEO Richard Lowenthal commented, “The decisive and unanimous opinion of the EPO committee in rejecting all of the opposition arguments and upholding the novel claims in our European patent supports the strength and validity of our extensive patent portfolio. These positive outcomes with our EP patent on top of the earlier IPR and Appeals court decisions on one of our US methods of use patents, provide confidence in our ability to overcome future patent challenges to our worldwide patent estate that covers intranasal epinephrine.”
Read the ARS Pharma press release
